Doxycycline interferes with tau amyloid aggregation abolishing its associated neuronal toxicity
| Autor: | Antonio Dominguez-Meijide, Rosana Chehín, Markus Zweckstetter, Florencia González-Lizárraga, Sequeira S, Laura Smeldy Jurado Medina, Tiago F. Outeiro, Del Bel E, Sergio B. Socías, Parrales, Maria-Sol Cima-Omori, R. Raisman-Vozari, Patrick P. Michel, Diego Ploper |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Doxycycline
Drug Gene isoform 0303 health sciences biology Chemistry media_common.quotation_subject Tau protein Neuronal toxicity Pharmacology 3. Good health 03 medical and health sciences 0302 clinical medicine Toxicity Amyloid aggregation medicine biology.protein 030217 neurology & neurosurgery 030304 developmental biology medicine.drug media_common |
| DOI: | 10.1101/2020.11.18.388561 |
| Popis: | Tauopathies are neurodegenerative disorders with increasing incidence and still without cure. The extensive time required for development and approval of novel therapeutics highlights the need for testing and repurposing known safe molecules. Since doxycycline impacts α-synuclein aggregation and toxicity, herein we tested its effect on tau. We found that doxycycline reduces amyloid aggregation of the different isoforms of tau protein in a dose-dependent manner, remodeling the resultant species. Furthermore, doxycycline interacts with tau microtubule-binding domain preventing its aggregation. In a cell free system doxycycline also prevents tau seeding and in cell culture reduces toxicity of tau aggregates. Overall, our results expand the spectrum of action of doxycycline against aggregation-prone proteins, opening novel perspectives for its repurposing as a disease-modifying drug for tauopathies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|